ADC Therapeutics S.A. (ADCT)
NYSE NYSE Primary 
ADC Therapeutics (ADCT) Upgraded to Buy: Here's Why
ADC Therapeutics (ADCT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is ADC Therapeutics (ADCT) Stock Outpacing Its Medical Peers This Year?
Here is how ADC Therapeutics SA (ADCT) and Catalyst Pharmaceutical (CPRX) have performed compared to their sector so far this year.
ADC Therapeutics SA (ADCT) is a Great Momentum Stock: Should You Buy?
Does ADC Therapeutics SA (ADCT) have what it takes to be a top stock pick for momentum investors? Let's find out.
ADC Therapeutics SA (ADCT) Discusses Updated Results From LOTIS-7 Trial Evaluating ZYNLONTA Plus Glofitamab in Relapsed or Refractory DLBCL Transcript
ADC Therapeutics SA (ADCT) Discusses Updated Results From LOTIS-7 Trial Evaluating ZYNLONTA Plus Glofitamab in Relapsed or Refractory DLBCL Transcript
Is ADC Therapeutics (ADCT) Outperforming Other Medical Stocks This Year?
Here is how ADC Therapeutics SA (ADCT) and Catalyst Pharmaceutical (CPRX) have performed compared to their sector so far this year.
ADC Therapeutics (ADCT) Upgraded to Buy: Here's What You Should Know
ADC Therapeutics (ADCT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
ADC Therapeutics SA (ADCT) Q3 2025 Earnings Call Transcript
ADC Therapeutics SA ( ADCT ) Q3 2025 Earnings Call November 10, 2025 8:30 AM EST Company Participants Nicole Riley Ameet Mallik - CEO & Director Mohamed Zaki - Chief Medical Officer Jose Carmona - Chief Financial Officer Conference Call Participants Eric Schmidt - Cantor Fitzgerald & Co., Research Division Jenna Li - Jefferies LLC, Research Division Leonid Timashev - RBC Capital Markets, Research Division Sudan Loganathan - Stephens Inc., Research Division Presentation Operator Good morning, ladies and gentlemen, and welcome to the ADC Therapeutics Q3 2025 Earnings Conference Call. [Operator Instructions] This call is being recorded on Monday, November 10, 2025.
ADC Therapeutics SA (ADCT) Reports Q2 Loss, Tops Revenue Estimates
ADC Therapeutics SA (ADCT) came out with a quarterly loss of $0.5 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to a loss of $0.38 per share a year ago.
ADC Therapeutics SA (ADCT) Q2 2025 Earnings Call Transcript
ADC Therapeutics SA (NYSE:ADCT ) Q2 2025 Earnings Conference Call August 12, 2025 8:30 AM ET Company Participants Ameet Mallik - CEO & Director Jose I. Carmona - Chief Financial Officer Mohamed Zaki - Chief Medical Officer Nicole Riley - Corporate Participant Conference Call Participants Eric Thomas Schmidt - Cantor Fitzgerald & Co., Research Division Jenna Li - Jefferies LLC, Research Division Leonid Timashev - RBC Capital Markets, Research Division Michael Werner Schmidt - Guggenheim Securities, LLC, Research Division Sudan Naveen Loganathan - Stephens Inc., Research Division Operator Good morning, ladies and gentlemen, and welcome to the ADC Therapeutics SA ADCT Q2 2025 Earnings Conference Call.
Are Medical Stocks Lagging ADC Therapeutics (ADCT) This Year?
Here is how ADC Therapeutics SA (ADCT) and Alnylam Pharmaceuticals (ALNY) have performed compared to their sector so far this year.
ADC Therapeutics SA (ADCT) Reports Q1 Loss, Tops Revenue Estimates
ADC Therapeutics SA (ADCT) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to loss of $0.56 per share a year ago.
ADC Therapeutics SA (ADCT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
ADC Therapeutics (ADCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
